02/03/2016 UGA announced it has entered into a
collaborative research agreement with GeoVax Labs Inc
to develop and test ZIKA vaccine
Ted Ross, (above) director of UGA's Center for Vaccines and Immunology:
"We believe that the expertise of our researchers combined with GeoVax's vaccine platform can accelerate the development and testing of a vaccine for this fast-spreading viral disease," Ross said
"This important partnership with GeoVax is consistent with one of our highest priorities, namely to work effectively with industry to address important challenges facing the state, the nation and the world," said David Lee, UGA vice president for research.
Watch This Informative 3 Minute Clip Presented By GeoVax President and CEO Robert McNally Giving An Overview Of The Company
GeoVax Labs, Inc. operates as a biotechnology company. It focuses on developing vaccines that prevent and fight human immunodeficiency virus (HIV) infections, which result in acquired immunodeficiency syndrome (AIDS). The company's ongoing research and development programs are focused on the clinical development of its DNA and MVA vaccines for the prevention and/or treatment of HIV/AIDS. It is developing two clinical pathways for its vaccine candidates, as a preventative vaccine to prevent or control infection of individuals who are exposed to the HIV virus; and as a therapeutic vaccine to prevent development of AIDS in those individuals who have already been infected with the HIV virus. GeoVax Labs' preventative vaccine candidate is in a Phase IIa clinical trial. In addition to its clinical development program for its vaccine candidates, the company is conducting pre-clinical research on the impact of adding adjuvants (immune system stimulants) to the DNA priming component of its vaccine. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.